Treatment

Alpha-synuclein as a therapeutic target for Parkinson’s disease 2:26
Alpha-synuclein as a therapeutic target for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Searching for therapeutic targets for Parkinson’s disease 1:32
Searching for therapeutic targets for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease 1:46
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Future prospects in Parkinson’s disease 1:00
Future prospects in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
How can we develop better DMTs in Huntington’s disease? 1:25
How can we develop better DMTs in Huntington’s disease?
Anne Rosser • 23 Sep 2021
A multidisciplinary approach to providing care in Huntington’s disease 3:28
A multidisciplinary approach to providing care in Huntington’s disease
Anne Rosser • 23 Sep 2021
Update: novel disease-modifying treatments in development for Huntington’s disease 2:20
Update: novel disease-modifying treatments in development for Huntington’s disease
Anne Rosser • 23 Sep 2021
Phase I trial of fetal striatal cell transplantation in Huntington’s disease 2:58
Phase I trial of fetal striatal cell transplantation in Huntington’s disease
Anne Rosser • 23 Sep 2021
REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals 8:23
REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals
Robert Glanzman • 13 Oct 2021
Connectomic DBS: target discovery based on neuronal circuitry 2:25
Connectomic DBS: target discovery based on neuronal circuitry
Michael Fox • 29 Sep 2021
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS 4:34
Updates on RADIUS-R & RADIUS-P: elezanumab for patients with relapsing and progressive forms of MS
Bruce Cree • 21 Oct 2021
Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS 3:57
Using virtual placebo to assess long-term effect of siponimod on disability progression in SPMS
Bruce Cree • 21 Oct 2021
A score to predict treatment response in pediatric patients with multiple sclerosis 3:26
A score to predict treatment response in pediatric patients with multiple sclerosis
Ermelinda De Meo • 27 Oct 2021
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD 2:44
Updates on N-MOmentum: inebilizumab versus placebo in patients with NMOSD
Bruce Cree • 21 Oct 2021
Imaging guide for thrombectomy in acute ischemic stroke 5:19
Imaging guide for thrombectomy in acute ischemic stroke
Marc Fisher • 28 Sep 2021
The content of VJNeurology is intended for healthcare professionals